GoodRx Care vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Willow beats GoodRx Care overall, scoring 8.2/10 vs 6.2/10. GoodRx Care is more affordable at $119/mo vs $299/mo. Choose GoodRx Care for users who want fda-approved brand-name glp-1 access at marke. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of GoodRx Care and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

GoodRx Care

#48 of 48

6.2/10

GoodRx Care was restructured in late 2025 from a pay-per-visit model into a telemedicine subscription: $39/mo intro rate (through January 2026) → $119/mo standard. Medication is priced aggressively: Ozempic/Wegovy $199/mo intro for the first 2 fills, then $349/mo standard. Oral Wegovy pill available at $149-199/mo.

Visit GoodRx Care

Higher Rated

Willow

#8 of 48

8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow

Feature	GoodRx Care	Willow
Our Score	6.2/10	8.2/10
Starting Price	$119/mo	$299/mo
Medication Type	Brand	Compounded
Insurance Accepted	Yes	No
Best For	Users who want FDA-approved brand-name GLP-1 access at market-leading subscription pricing — $199/mo Wegovy intro, $349/mo standard, plus oral Wegovy pill	Users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking	#48	#8

Pros & Cons Compared

GoodRx Care

Pros

+2026 subscription rewrite — $119/mo standard membership with medication priced among the lowest on the market
+Wegovy/Ozempic intro pricing ($199/mo for first 2 fills) is market-leading for brand-name access
+Oral Wegovy pill available at $149-199/mo — one of the cheapest oral semaglutide routes
+Insurance accepted — GoodRx's integration with savings cards can stack with coverage

Cons

−Model changed from pay-per-visit to subscription — users expecting à-la-carte pricing should double-check current terms
−Compounded GLP-1s are de-emphasized on current marketing — may no longer be available
−Subscription model means ongoing monthly fee even in maintenance months
−Follow-up clinical care is still basic compared to dedicated GLP-1 platforms

Willow

Pros

+Includes monthly provider check-ins and dose adjustments at no extra cost
+Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
+$299/mo all-in for compounded semaglutide with monthly provider support
+90%+ patient retention rate after 3 months per their published outcomes data

Cons

−Compounded-only — no brand-name Wegovy or Zepbound through the platform
−Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
−Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
−Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Willow edges out GoodRx Care with a score of 8.2/10 vs 6.2/10. If budget is your priority, GoodRx Care starts at $119/mo compared to Willow's $299/mo. GoodRx Care accepts insurance, which can significantly reduce your out-of-pocket costs. Choose GoodRx Care if you want: users who want fda-approved brand-name glp-1 access at market-leading subscription pricing — $199/mo wegovy intro, $349/mo standard, plus oral wegovy pill. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither GoodRx Care nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review